Laden…
4-chloro-N-(2-morpholin-4-ylethyl)benzamide
Moclobemide is a reversible selective inhibitor of monoamine oxidase A (MAO-A), primarily used for the treatment of depression. It increases the concentration of monoamines such as serotonin, norepinephrine, and dopamine in the synaptic cleft without causing irreversible enzyme inhibition. Due to its reversible action, the risk of severe adverse effects and interactions is lower than with classical irreversible MAO inhibitors. However, interactions with certain foods and medications are possible, so caution is advised.
Class
MAO-Hemmer
Pharmacological context
Mechanism
MAO-A inhibitor
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Moclobemide acts through the following pharmacological mechanisms:
Designations
IUPAC: 4-chloro-N-(2-morpholinoethyl)benzamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der 5-HT1A-Rezeptor ist ein Gi/Go-gekoppelter Serotoninrezeptor, der als Autorezeptor auf serotonergen Neuronen und als Heterorezeptor in verschiedenen Hirnregionen vorkommt. Er moduliert Angst, Stimmung und Kognition.
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulants und Antidepressiva beeinflusst.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Monoaminoxidase A (MAO-A) ist ein mitochondriales Enzym, das Serotonin, Noradrenalin und Dopamin oxidativ desaminiert. Hemmung führt zu erhöhten Monoamin-Spiegeln und ist die Grundlage der MAO-Hemmer-Therapie bei Depression.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Reported range 300 mg/day
Total duration 24 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 150 mg/day |
| Reported | 300 mg/day |
| Strong | 600 mg/day |
Oral
Onset
1–2 weeks
Peak
4–6 weeks
Total duration
24 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Moclobemid kann Wechselwirkungen mit anderen Medikamenten haben und sollte mit Vorsicht angewendet werden.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.